CBChristopher F. Barnett

Christopher F. Barnett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher F. Barnett has a total of 450 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hyperoxia reflects poor native cardiac function and demonstrates cardiac index-dependent associations with mortality in veno-arterial extracorporeal membrane oxygenation patients

    by Ryan K Ruaysungnoen, Anja Strehlow, Sylvie Baudart, Yu Wu, Amy G Fiedler, Christopher F Barnett, Jason W Smith, Pablo A Sanchez, Liviu Klein, Samuel B Brusca, et al.

    Aims: Multiple veno-arterial extracorporeal membrane oxygenation (VA-ECMO) studies have recently reported that early hyperoxia is associated with increased mortality; yet, the underlying mechanism is unclear. As prior analyses did not account for native cardiac output or fraction of delivered oxygen, it remains unknown whether hyperoxia is directly injurious or primarily a surrogate of poor intrinsic cardiac function and proximal mixing. This study aims to evaluate whether hyperoxia is an independent predictor of mortality in VA-ECMO patients or whether it primarily reflects impaired native cardiac function. Methods and results: We conducted a single-centre retrospective cohort study of 227 VA-ECMO patients to evaluate the relationship between hyperoxia and intensive care unit (ICU) mortality, accounting for native cardiac index using multivariable regression and principal component analysis. Average PaO2 and cardiac index were analysed as continuous variables. Decreased cardiac index was the strongest independent predictor of ICU mortality in a multivariable regression [odds ratio (OR) 0.22; 95% confidence interval (CI): 0.06–0.70; P = 0.018]. After adjusting for native cardiac index and utilization of advanced therapies (i.e. heart transplant or left ventricular assist device), the association between hyperoxia and mortality became insignificant. Average PaO2 and cardiac index were strongly inversely collinear [variance inflation factor (VIF) = 7.2 and 11.5, respectively], with their interaction term yielding a VIF of 20.3. Non-survivors and survivors who received advanced therapies share similar PC1 score distributions (a weighted composite of average PaO2 and cardiac index) and impaired haemodynamic profiles, including reduced ejection fraction, pulse pressures, and oxygen delivery indices. Conclusion: The association between early hyperoxia and mortality in VA-ECMO is primarily driven by underlying cardiac failure rather than direct oxygen toxicity. The availability of advanced therapies further modifies this relationship, underscoring the need to account for both native cardiac output and heart replacement strategies when evaluating optimal PaO2 targets and the independent effect of hyperoxia on VA-ECMO outcomes.


  • The Society of Critical Care Cardiology—Rationale, blueprint, and lessons learned in the creation of a new multidisciplinary professional organization

    by Balimkiz Senman, P. Elliott Miller, Ann Gage, David M. Dudzinski, Carlos Alviar, Diego Araiza-Garaygordobil, Alexandra Arias-Mendoza, Alexis Barnes, Christopher Barnett, Mir B. Basir, et al.


  • Open Access

    Reply

    by Alexander I. Papolos, Christopher F. Barnett, Jacob C. Jentzer

  • Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN)

    by David E. Hamilton, Jackson L. Shriver, Siddharth M. Patel, Jeong-Gun Park, Zoe E. Michos, Michael R. Mathis, Sarah K. Adie, Carlos L. Alviar, Christopher F. Barnett, David D. Berg, et al.

    BACKGROUND: The paucity of data to guide selection of specific vasoactive agents in patients with cardiogenic shock (CS) may lead to variability in practice patterns. The level of variability and specific factors that are associated with the use of vasoactive medications and inodilators have not been previously described. METHODS: The CCCTN (Critical Care Cardiology Trials Network) is an international, multicenter network of cardiac intensive care units (CICUs) coordinated by the TIMI Study Group. This analysis included CICU admissions for CS from 2019 to 2023. Variation in the use of inodilator treatment (dobutamine/milrinone) was assessed with multivariable mixed-effects logistic modeling. RESULTS: A total of 3282 admissions from 37 CICUs comprised the analysis cohort. The use of vasoactive medications, including inodilator treatment, varied substantially across institutions. Patient-level variables associated with greater use of inodilators included history of heart failure (odds ratio, 1.98 [95% CI, 1.61–2.44]), biventricular failure (1.59 [95% CI, 1.27–2.00]), Society of Cardiovascular Angiography and Interventions stage D (1.34 [95% CI, 1.07–1.68]), valvular disease (1.34 [95% CI, 1.03–1.74]), and male sex (1.23 [95% CI, 1.02–1.49]). Variables associated with less inodilator use included cardiac arrest (0.33 [95% CI, 0.27–0.42]), right ventricular failure (0.50 [95% CI, 0.33–0.73]), Society of Cardiovascular Angiography and Interventions stage E (0.57 [95% CI, 0.41–0.81]), acute myocardial infarction-CS (0.71 [95% CI, 0.56–0.90]), peripheral arterial disease (0.73 [95% CI, 0.54–0.99]), older age (0.77 [95% CI, 0.72–0.83], per 10-year increase), and estimated glomerular filtration rate (0.96 [95% CI, 0.93–0.99], per 10 mL/min per 1.73 m 2 increase). No individual measurable institution-level factors (eg, transplant center) were associated with variability in inodilator use. In mixed-effects logistic modeling, 45.7% of variation in inodilator use was attributed to patient-level factors and 22.7% to the random effect of individual CICU centers. Similarly, 35.3% of variation in the use of dobutamine versus milrinone was attributed to patient-level factors and 32.6% to the random effect of individual CICU centers. CONCLUSIONS: There is significant variation in vasoactive treatment and inodilator use in CS. Variation in inodilator use was associated with patient-level factors and with substantial individual CICU practice variation. Such variability underscores the need for additional high-quality evidence to guide vasoactive treatment strategies in CS.


  • Open Access

    Physician Burnout and Work Satisfaction in the Cardiac Intensive Care Unit

    by Samuel B. Brusca, Alexander I. Papolos, Michael A. Solomon, Robert O. Roswell, Rosy Thachil, Benjamin Kenigsberg, Sunit-Preet Chaudhry, Eugene Yuriditsky, Ran Lee, Alejandra Gutierrez, et al.

  • Open Access

    Cardiovascular complications are rare in severe COVID-19 presenting with myocardial injury

    by Connor G O’brien, Fatma Gunturkun, Wei Deng, Donald Chang, Sameer Khanijo, Christopher F Barnett, Shikha Kapil, Andrea Daly, Alberto Goffi, Dekel Stavi, et al.

    Background: SARS-COV2 infection has been linked to cardiovascular complications. Previously published data suggested that cardiac injury may be a common disease feature and contribute to morbidity and mortality in severe COVID-19. Since the early days of the pandemic, little data has emerged describing what cardiovascular complications arise from myocardial injury in severe COVID-19 and whether these complications contribute to mortality. Objectives: Describe the incidence and nature of cardiovascular complications in patients with severe COVID-19 infection and biochemical or imaging evidence of myocardial injury. Methods: We analyzed consecutive patients admitted for severe COVID-19 and presenting with biochemical or echocardiographic evidence of myocardial injury across 16 centers within the CARDIO-COVID investigator-initiated consortium. A light-GBM machine learning model was used to identify variables associated with mortality. Results: Our study included 1,328 patients. In hospital mortality was 29.4%. Factors most associated with mortality were age, SOFA Cardiovascular score, elevated troponin, intubation, high vasoactive-inotropic score (VIS), high PEEP, and high FiO2. Cardiovascular complications were rare and did not present significant association with mortality. Patients with high VIS and SOFA Cardiovascular scores had a significantly higher incidence of secondary bacterial pneumonias suggesting septic shock played a role in their physiology. Investigator-adjudicated cause of death data identified respiratory failure and septic shock as primary causes of mortality. Conclusions: Cardiovascular complications of severe COVID-19 are uncommon and do not seem to contribute significantly to mortality. Biochemical markers of myocardial injury or strain still carry significant prognostic value, but the value of these markers may indicate presence of high-risk ARDS phenotypes as opposed to significant myocardial injury.

  • Open Access

    Modern Cardiac ICU Care Delivery and the Role of the Cardiac ICU Cardiologist

    by Alexander I. Papolos, Samuel B. Brusca, Christopher F. Barnett, Benjamin B. Kenigsberg, Robert O. Roswell, Michael A. Solomon, Alejandra Gutierez, Ran Lee, Rosy Thachil, Jason N. Katz, et al.


  • Open Access

    Characteristics and Survival Among Patients With Cardiogenic Shock Undergoing Mitral Transcatheter Edge-to-Edge Repair

    by Leila Haghighat, Richard Cheng, Christopher F. Barnett, Samuel B. Brusca, Jeong-Gun Park, Anthony P. Carnicelli, Andrew H. Nguyen, Raunak M. Nair, David A. Morrow, Connor G. O’bRien


  • Open Access

    Association Between Pressure-Adjusted Heart Rate and In-Hospital Mortality in Cardiogenic Shock

    by Curtis R. Ginder, Jacob C. Jentzer, Siddharth M. Patel, Erin A. Bohula, Carlos E. Alfonso, Christopher F. Barnett, Gregory W. Barsness, Mark W. Dodson, Shahab Ghafghazi, Umesh Gidwani, et al.


  • Open Access

    Critical Care Cardiology

    by Barinder S. Hansra, Andrea M. Elliott, Ann Gage, Christopher F. Barnett, Brandon Wiley